UnitedHealth Group CEO Stephen Hemsley faces intense investor scrutiny Tuesday as the company reports second-quarter earnings, according to CNBC. The company is grappling with criminal and civil DOJ probes, collapsing Optum Health margins, and suspended 2025 guidance. UnitedHealth shares have nearly halved since May following sharp profit drops in Medicare Advantage and physician services, prompting the return of Hemsley after CEO Andrew Witty resigned. Analysts are watching for revised full-year EPS guidance, expected at $21.26, and clarity on how Optum Health will recover after billing changes under Medicare’s V28 rules. While some analysts expressed cautious optimism, they expressed concern over misexecution and long-term challenges.
